This page has only limited features, please log in for full access.

Unclaimed
Pierluca Piselli
National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Via Portuense, 292, 00149 Rome, Italy

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 22 July 2021 in Journal of Clinical Medicine
Reads 0
Downloads 0

Introduction: The use of steroid therapy in patients within the context of SARS-CoV-2 infection is still a matter of debate. This study aimed to evaluate if potential steroid benefits could be predicted by the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2) (P/F) in COVID-19 patients at admission. Materials and Methods: Medical records were retrospectively collected from all adult patients admitted because of COVID-19 from 29 January to 31 July 2020. The association of steroid therapy with 28-day all-cause mortality outcome was analysed in a multivariable logistic regression model adjusted for confounding factors. Results: Overall, 511 patients were analysed, of which 39.1% underwent steroid therapy. Steroid treated patients were mostly male, older, and more frequently treated with antiviral drugs and aminoquinolines; the most common comorbidities were hypertension, followed by cardiovascular disease. Overall, 51 patients died within 28-days, and overall 28-days mortality was 19.5% in the cohort of patients exposed to steroids versus 3.9% mortality in unexposed patients (p< 0.001). Steroid therapy on patients with P/F ratio of 235 mmHg or higher at admission can be considered as detrimental, with an 8% increased probability of death. Conclusions: Steroid therapy is associated with increased 28-day mortality in COVID-19 in patients with mild or no ARDS.

ACS Style

Serena Vita; Daniele Centanni; Simone Lanini; Pierluca Piselli; Silvia Rosati; Maria Giancola; Annalisa Mondi; Carmela Pinnetti; Simone Topino; Pierangelo Chinello; Silvia Mosti; Gina Gualano; Francesca Faraglia; Fabio Iacomi; Luisa Marchioni; Micaela Maritti; Enrico Girardi; Giuseppe Ippolito; Emanuele Nicastri; on behalf of the ReCOVeRI Study Group. Benefits of Steroid Therapy in COVID-19 Patients with Different PaO2/FiO2 Ratio at Admission. Journal of Clinical Medicine 2021, 10, 3236 .

AMA Style

Serena Vita, Daniele Centanni, Simone Lanini, Pierluca Piselli, Silvia Rosati, Maria Giancola, Annalisa Mondi, Carmela Pinnetti, Simone Topino, Pierangelo Chinello, Silvia Mosti, Gina Gualano, Francesca Faraglia, Fabio Iacomi, Luisa Marchioni, Micaela Maritti, Enrico Girardi, Giuseppe Ippolito, Emanuele Nicastri, on behalf of the ReCOVeRI Study Group. Benefits of Steroid Therapy in COVID-19 Patients with Different PaO2/FiO2 Ratio at Admission. Journal of Clinical Medicine. 2021; 10 (15):3236.

Chicago/Turabian Style

Serena Vita; Daniele Centanni; Simone Lanini; Pierluca Piselli; Silvia Rosati; Maria Giancola; Annalisa Mondi; Carmela Pinnetti; Simone Topino; Pierangelo Chinello; Silvia Mosti; Gina Gualano; Francesca Faraglia; Fabio Iacomi; Luisa Marchioni; Micaela Maritti; Enrico Girardi; Giuseppe Ippolito; Emanuele Nicastri; on behalf of the ReCOVeRI Study Group. 2021. "Benefits of Steroid Therapy in COVID-19 Patients with Different PaO2/FiO2 Ratio at Admission." Journal of Clinical Medicine 10, no. 15: 3236.

Journal article
Published: 10 April 2021 in Viruses
Reads 0
Downloads 0

SARS-CoV-2 serum neutralization assay represents the gold standard for assessing antibody-mediated protection in naturally infected and vaccinated individuals. In the present study, 662 serum samples collected from February 2020 to January 2021 from acute and convalescent COVID-19 patients were tested to determine neutralizing antibody (NAb) titers using a microneutralization test (MNT) for live SARS-CoV-2. Moreover, anti-SARS-CoV-2 IgG, IgA, and IgM directed against different viral antigens were measured by high-throughput automated platforms. We observed higher levels of NAbs in elderly (>60 years old) individuals and in patients presenting acute respiratory distress syndrome. SARS-CoV-2 NAbs develop as soon as five days from symptom onset and, despite a decline after the second month, persist for over 11 months, showing variable dynamics. Through correlation and receiver operating characteristic (ROC) curve analysis, we set up a testing algorithm, suitable for the laboratory workload, by establishing an optimal cutoff value of anti-SARS-CoV-2 IgG for convalescent plasma donors to exclude from MNT samples foreseen to have low/negative NAb titers and ineligible for plasma donation. Overall, MNT, although cumbersome and not suitable for routine testing of large sample sizes, remains the reference tool for the assessment of antibody-mediated immunity after SARS-CoV-2 infection. Smart testing algorithms may optimize the laboratory workflow to monitor antibody-mediated protection in COVID-19 patients, plasma donors, and vaccinated individuals.

ACS Style

Giulia Matusali; Francesca Colavita; Daniele Lapa; Silvia Meschi; Licia Bordi; Pierluca Piselli; Roberta Gagliardini; Angela Corpolongo; Emanuele Nicastri; Andrea Antinori; Giuseppe Ippolito; Maria Rosaria Capobianchi; Concetta Castilletti. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses 2021, 13, 655 .

AMA Style

Giulia Matusali, Francesca Colavita, Daniele Lapa, Silvia Meschi, Licia Bordi, Pierluca Piselli, Roberta Gagliardini, Angela Corpolongo, Emanuele Nicastri, Andrea Antinori, Giuseppe Ippolito, Maria Rosaria Capobianchi, Concetta Castilletti. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses. 2021; 13 (4):655.

Chicago/Turabian Style

Giulia Matusali; Francesca Colavita; Daniele Lapa; Silvia Meschi; Licia Bordi; Pierluca Piselli; Roberta Gagliardini; Angela Corpolongo; Emanuele Nicastri; Andrea Antinori; Giuseppe Ippolito; Maria Rosaria Capobianchi; Concetta Castilletti. 2021. "SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus." Viruses 13, no. 4: 655.

Journal article
Published: 23 February 2021 in International Journal of Environmental Research and Public Health
Reads 0
Downloads 0

Since December 2019, SARS-CoV-2 infection has been still rapidly spreading, resulting in a pandemic, followed by an increasing number of cases in countries throughout the world. The severity of the disease depends on the patient’s overall medical condition but no appropriate markers are available to establish the prognosis of the patients. We performed a 16S rRNA gene sequencing, revealing an altered composition of the nasal/oropharyngeal (NOP) microbiota in 21 patients affected by COVID-19, paucisymptomatic or in an Intensive Care Unit (ICU), as compared to 10 controls negative for COVID-19 or eight affected by a different Human Coronavirus (HKU, NL63 and OC43). A significant decrease in Chao1 index was observed when patients affected by COVID-19 (in ICU) were compared to paucisymptomatic. Furthermore, patients who were in ICU, paucisymptomatic or affected by other Coronaviruses all displayed a decrease in the Chao1 index when compared to controls, while Shannon index significantly decreased only in patients under ICU as compared to controls and paucisymptomatic patients. At the phylum level, Deinococcus-Thermus was present only in controls as compared to SARS-CoV-2 patients admitted to ICU, paucisymptomatic or affected by other coronaviruses. Candidatus Saccharibacteria (formerly known as TM7) was strongly increased in negative controls and SARS-CoV-2 paucisymptomatic patients as compared to SARS-CoV-2 ICU patients. Other modifications were observed at a lower taxonomy level. Complete depletion of Bifidobacterium and Clostridium was exclusively observed in ICU SARS-CoV-2 patients, which was the only group characterized by the presence of Salmonella, Scardovia, Serratia and Pectobacteriaceae. In conclusion, our preliminary results showed that nasal/oropharyngeal microbiota profiles of patients affected with SARS-CoV-2 may provide valuable information in order to facilitate the stratification of patients and may open the way to new interventional strategies in order to ameliorate the outcome of the patients.

ACS Style

Martina Rueca; Andrea Fontana; Barbara Bartolini; Pierluca Piselli; Antonio Mazzarelli; Massimiliano Copetti; Elena Binda; Francesco Perri; Cesare Gruber; Emanuele Nicastri; Luisa Marchioni; Giuseppe Ippolito; Maria Capobianchi; Antonino Di Caro; Valerio Pazienza. Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing. International Journal of Environmental Research and Public Health 2021, 18, 2174 .

AMA Style

Martina Rueca, Andrea Fontana, Barbara Bartolini, Pierluca Piselli, Antonio Mazzarelli, Massimiliano Copetti, Elena Binda, Francesco Perri, Cesare Gruber, Emanuele Nicastri, Luisa Marchioni, Giuseppe Ippolito, Maria Capobianchi, Antonino Di Caro, Valerio Pazienza. Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing. International Journal of Environmental Research and Public Health. 2021; 18 (4):2174.

Chicago/Turabian Style

Martina Rueca; Andrea Fontana; Barbara Bartolini; Pierluca Piselli; Antonio Mazzarelli; Massimiliano Copetti; Elena Binda; Francesco Perri; Cesare Gruber; Emanuele Nicastri; Luisa Marchioni; Giuseppe Ippolito; Maria Capobianchi; Antonino Di Caro; Valerio Pazienza. 2021. "Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing." International Journal of Environmental Research and Public Health 18, no. 4: 2174.

Original article
Published: 25 January 2021 in Transplant International
Reads 0
Downloads 0

Background Patients with hepatocellular carcinoma (HCC) are at high risk of second primary malignancies. As HCC has become the leading indication of liver transplant (LT), the aim of this study was to investigate whether the presence of HCC before LT could influence the onset of de novo malignancies (DNM). Methods A cohort study was conducted on 2653 LT recipients. Hazard ratios (HR) of DNM development for patients transplanted for HCC (HCC patients) were compared with those of patients without any previous malignancy (non‐HCC patients). All models were adjusted for sex, age, calendar year at transplant, and liver disease etiology. Results Throughout 17,903 person‐years, 6.6% of HCC patients and 7.4% of non‐HCC patients developed DNM (202 cases). The median time from LT to first DNM diagnosis was shorter for solid tumors in HCC patients (2.7 vs 4.5 years for HCC and non‐HCC patients, respectively, p<0.01). HCC patients were at a higher risk of bladder cancer and skin melanoma. There were no differences in cumulative DNM‐specific mortality by HCC status. Conclusions This study suggests that primary HCC could be a risk factor for DNM in LT recipients, allowing for risk stratification and screening individualization.

ACS Style

Sarah Shalaby; Martina Taborelli; Alberto Zanetto; Alberto Ferrarese; Francesca D’Arcangelo; Martina Gambato; Marco Senzolo; Francesco Paolo Russo; Giacomo Germani; Patrizia Boccagni; Giuseppe Maria Ettorre; Umberto Baccarani; Augusto Lauro; Laura Galatioto; Maria Rendina; Raffaella Petrara; Anita De Rossi; Francesco Nudo; Luca Toti; Giovanni Fantola; Giovanni Vennarecci; Andrea Risaliti; Antonio Daniele Pinna; Salvatore Gruttadauria; Alfredo Di Leo; Massimo Rossi; Giuseppe Tisone; Fausto Zamboni; Umberto Cillo; Pierluca Piselli; Diego Serraino; Patrizia Burra; Italian Transplant and Cancer Cohort Study. Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation – a multicenter cohort study. Transplant International 2021, 34, 743 -753.

AMA Style

Sarah Shalaby, Martina Taborelli, Alberto Zanetto, Alberto Ferrarese, Francesca D’Arcangelo, Martina Gambato, Marco Senzolo, Francesco Paolo Russo, Giacomo Germani, Patrizia Boccagni, Giuseppe Maria Ettorre, Umberto Baccarani, Augusto Lauro, Laura Galatioto, Maria Rendina, Raffaella Petrara, Anita De Rossi, Francesco Nudo, Luca Toti, Giovanni Fantola, Giovanni Vennarecci, Andrea Risaliti, Antonio Daniele Pinna, Salvatore Gruttadauria, Alfredo Di Leo, Massimo Rossi, Giuseppe Tisone, Fausto Zamboni, Umberto Cillo, Pierluca Piselli, Diego Serraino, Patrizia Burra, Italian Transplant and Cancer Cohort Study. Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation – a multicenter cohort study. Transplant International. 2021; 34 (4):743-753.

Chicago/Turabian Style

Sarah Shalaby; Martina Taborelli; Alberto Zanetto; Alberto Ferrarese; Francesca D’Arcangelo; Martina Gambato; Marco Senzolo; Francesco Paolo Russo; Giacomo Germani; Patrizia Boccagni; Giuseppe Maria Ettorre; Umberto Baccarani; Augusto Lauro; Laura Galatioto; Maria Rendina; Raffaella Petrara; Anita De Rossi; Francesco Nudo; Luca Toti; Giovanni Fantola; Giovanni Vennarecci; Andrea Risaliti; Antonio Daniele Pinna; Salvatore Gruttadauria; Alfredo Di Leo; Massimo Rossi; Giuseppe Tisone; Fausto Zamboni; Umberto Cillo; Pierluca Piselli; Diego Serraino; Patrizia Burra; Italian Transplant and Cancer Cohort Study. 2021. "Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation – a multicenter cohort study." Transplant International 34, no. 4: 743-753.

Journal article
Published: 20 October 2020 in Viruses
Reads 0
Downloads 0

Background: RT-PCR on nasopharyngeal (NPS)/oropharyngeal swabs is the gold standard for diagnosis of SARS-CoV-2 infection and viral load monitoring. Oral fluid (OF) is an alternate clinical sample, easy and safer to collect and could be useful for COVID-19 diagnosis, monitoring viral load and shedding. Methods: Optimal assay conditions and analytical sensitivity were established for the commercial Simplexa™ COVID-19 Direct assay adapted to OF matrix. The assay was used to test 337 OF and NPS specimens collected in parallel from 164 hospitalized patients; 50 bronchoalveolar lavage (BAL) specimens from a subgroup of severe COVID-19 cases were also analysed. Results: Using Simplexa™ COVID-19 Direct on OF matrix, 100% analytical detection down to 1 TCID50/mL (corresponding to 4 × 103 copies (cp)/mL) was observed. No crossreaction with other viruses transmitted through the respiratory toute was observed. Parallel testing of 337 OF and NPS samples showed highly concordant results (κ = 0.831; 95 % CI = 0.771–0.891), and high correlation of Ct values (r = 0.921; p < 0.0001). High concordance and elevated correlation was observed also between OF and BAL. Prolonged viral RNA shedding was observed up to 100 days from symptoms onset (DSO), with 32% and 29% positivity observed in OF and NPS samples, respectively, collected between 60 and 100 DSO. Conclusions: Simplexa™ COVID-19 Direct assays on OF have high sensitivity and specificity to detect SARS-CoV-2 RNA and provide an alternative to NPS for diagnosis and monitoring SARS-CoV-2 shedding.

ACS Style

Licia Bordi; Giuseppe Sberna; Eleonora Lalle; Pierluca Piselli; Francesca Colavita; Emanuele Nicastri; Andrea Antinori; Evangelo Boumis; Nicola Petrosillo; Luisa Marchioni; Giulia Minnucci; Elena D’Agostini; Concetta Castilletti; Franco Locatelli; Alimuddin Zumla; Giuseppe Ippolito; Maria Capobianchi; on behalf of INMI ReCOVeRI Study Group. Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay. Viruses 2020, 12, 1184 .

AMA Style

Licia Bordi, Giuseppe Sberna, Eleonora Lalle, Pierluca Piselli, Francesca Colavita, Emanuele Nicastri, Andrea Antinori, Evangelo Boumis, Nicola Petrosillo, Luisa Marchioni, Giulia Minnucci, Elena D’Agostini, Concetta Castilletti, Franco Locatelli, Alimuddin Zumla, Giuseppe Ippolito, Maria Capobianchi, on behalf of INMI ReCOVeRI Study Group. Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay. Viruses. 2020; 12 (10):1184.

Chicago/Turabian Style

Licia Bordi; Giuseppe Sberna; Eleonora Lalle; Pierluca Piselli; Francesca Colavita; Emanuele Nicastri; Andrea Antinori; Evangelo Boumis; Nicola Petrosillo; Luisa Marchioni; Giulia Minnucci; Elena D’Agostini; Concetta Castilletti; Franco Locatelli; Alimuddin Zumla; Giuseppe Ippolito; Maria Capobianchi; on behalf of INMI ReCOVeRI Study Group. 2020. "Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay." Viruses 12, no. 10: 1184.

Original paper
Published: 09 June 2020 in Journal of Digital Imaging
Reads 0
Downloads 0

To assess the incidence of outpatient examinations delivered through a web portal in the Latium Region in 2 years and compare socio-demographic characteristics of these users compared to the total of examinations performed. All radiological exams (including MRI, X-ray and CT) performed from March 2017 to February 2019 were retrospectively analysed. For each exam, anonymized data of users who attended the exam were extracted and their characteristics were compared according to digital access to the reports. Overall, 9068 exams were performed in 6720 patients (55.8% males, median age 58 years, interquartile range (IQR) 46–70) of which 90.2% residents in Rome province, mainly attending a single radiological examination (77.3%). Among all exams, 446 (4.9%) were accessed, of which 190 (4.4%) in the first and 5.4% in the second year (p < 0.041). MRI was the type of exams mostly accessed (175, 7.0%). Being resident in the provinces of the Latium Region other than Rome was associated with a higher access rate (OR = 1.84, p = 0.001). Considering the overall costs sustained to implement a web portal which allows users a personal access to their own reports, if all users would have accessed/downloaded their exams, an overall users’ and hospital savings up to €255,808.28 could have been determined. The use of a web portal could represent a consistent economical advantage for the user, the hospital and the environment. Even if increasing over time, the use of web portal is still limited and strategies to increase the use of such systems should be implemented.

ACS Style

Massimo Cristofaro; Pierluca Piselli; Elisa Pianura; Ada Petrone; Claudia Cimaglia; Federica Di Stefano; Fabrizio Albarello; Vincenzo Schininà. Patient Access to an Online Portal for Outpatient Radiological Images and Reports: Two Years’ Experience. Journal of Digital Imaging 2020, 33, 1479 -1486.

AMA Style

Massimo Cristofaro, Pierluca Piselli, Elisa Pianura, Ada Petrone, Claudia Cimaglia, Federica Di Stefano, Fabrizio Albarello, Vincenzo Schininà. Patient Access to an Online Portal for Outpatient Radiological Images and Reports: Two Years’ Experience. Journal of Digital Imaging. 2020; 33 (6):1479-1486.

Chicago/Turabian Style

Massimo Cristofaro; Pierluca Piselli; Elisa Pianura; Ada Petrone; Claudia Cimaglia; Federica Di Stefano; Fabrizio Albarello; Vincenzo Schininà. 2020. "Patient Access to an Online Portal for Outpatient Radiological Images and Reports: Two Years’ Experience." Journal of Digital Imaging 33, no. 6: 1479-1486.

Chest radiology
Published: 11 February 2020 in La radiologia medica
Reads 0
Downloads 0

To evaluate the effect of dose reduction with iterative reconstruction (IR) on image quality of chest CT scan comparing two protocols. Fifty-nine patients were enrolled. The two CT protocols were applied using Iterative Reconstruction (ASIR™) 40% but different noise indexes, recording dose-length product (DLP) and volume computed tomography dose index (CTDIvol). The subjective IQ was rated based on the distinction of anatomic details using a 4-point Likert scale based on the European Guidelines on Quality Criteria for CT. For each patient, two single CTs, at enrollment (group 1) and at follow-up after lowering the dose (group 2), were evaluated by two radiologists evaluating, for each examination, five different lung regions (central zone—CZ; peripheral zone—PZ; sub-pleural region—SPR; centrilobular region—CLR; and apical zone—AZ). An inter-observer agreement was expressed by weighted Cohen’s kappa statistics (k) and intra-individual differences of subjective image analysis through visual grading characteristic (VGC) analysis. An average 50.4% reduction in CTDIvol and 51.5% reduction in DLP delivered were observed using the dose-reduced protocol. An agreement between observers evaluating group 1 CTs was perfect (100%) and moderate to good in group 2 examinations (k-Cohen ranging from 0.56 for PZ and AZ to 0.70 for SPR). In the VGC analysis, image quality ratings were significantly better for group 1 than group 2 scans for all regions (AUCVGC ranging from 0.56 for CZ to 0.62). However, disagreement was limited to a score 4 (excellent)-to-score 3 (good) IQ transition; apart from a single case in PZ, both the observers scored the IQ at follow-up as 2 (sufficient) starting from a score 4 (excellent). Dose reduction achieved in the follow-up CT scans, although a lower IQ still allows a good diagnostic confidence.

ACS Style

Massimo Cristofaro; Elisa Busi Rizzi; Pierluca Piselli; Elisa Pianura; Ada Petrone; Nicoletta Fusco; Federica di Stefano; Vincenzo Schinina'. Image quality and radiation dose reduction in chest CT in pulmonary infection. La radiologia medica 2020, 125, 451 -460.

AMA Style

Massimo Cristofaro, Elisa Busi Rizzi, Pierluca Piselli, Elisa Pianura, Ada Petrone, Nicoletta Fusco, Federica di Stefano, Vincenzo Schinina'. Image quality and radiation dose reduction in chest CT in pulmonary infection. La radiologia medica. 2020; 125 (5):451-460.

Chicago/Turabian Style

Massimo Cristofaro; Elisa Busi Rizzi; Pierluca Piselli; Elisa Pianura; Ada Petrone; Nicoletta Fusco; Federica di Stefano; Vincenzo Schinina'. 2020. "Image quality and radiation dose reduction in chest CT in pulmonary infection." La radiologia medica 125, no. 5: 451-460.

Multicenter study
Published: 23 December 2019 in PLOS ONE
Reads 0
Downloads 0

A significant proportion of HIV-infected patients experiencing a late diagnosis highlights the need to define immunological protocols able to help the clinicians in identifying patients at higher risk for immunological failure. The aim of the study was to evaluate the feasibility of easy cytometric tests in defining the effect of antiretroviral treatment (cART) on immunological homeostasis and in identifying predictive markers of early immune recovery. Chronic HIV infected patients (n = 202) were enrolled in a prospective multicentric study, and their immunological profile was studied before (w0) and after 24 weeks (w24) of antiretroviral treatment (cART) using a standardized flow cytometric panel. Based on CD4 T cell count before treatment, patients were divided in late (LP: CD4 500/mmc) presenters. In all groups, cART introduction increased CD4 and CD4/CD8 T cell ratio, naïve T cell (CD4 and CD8) and CD127-expressing CD4 T cells. In parallel, cART significantly reduced effector memory T cells (CD4 and CD8) and T cell activation (CD38+CD8 and CD95+CD4 T cells). Moreover, the frequency of Naïve and Effector CD4 T cells before treatment correlated with several immune parameters key associated with the pathogenesis of HIV, thus mirroring the health of immune system. Interestingly, we identified the Naïve/Effector CD4 T cell ratio (N/EM) at w0 as a marker able to predict early immune recovery. Specifically, in LP, N/EM ratio was significantly higher in immunological responder patients (CD4>500/mmc at w24) when compared to immunological non responder (CD4 T cells <500/mmc at w24). Finally, a multivariate analysis indicates that after 24w patients with N/EM ratio higher than 1.86 at w0 recovered 96 CD4 T cells more than those with N/EM ratio lower than 0.46. Altogether, our data define an easy protocol able to define reliable immunological markers useful for the characterization of immune profile in viremic HIV patients and identify the naïve/effector CD4 T cell ratio as a new tool able to predict an early immune reconstitution potential.

ACS Style

Veronica Bordoni; Bruno Brando; Pierluca Piselli; Olindo Forini; Federico Enrico Perna; Umberto Atripaldi; Sara Carputo; Federica Garziano; Elisabetta Trento; Giovanna D'Agosto; Alessandra Latini; Manuela Colafigli; Antonio Cristaudo; Alessandra Sacchi; Massimo Andreoni; Gabriella De Carli; Nicoletta Orchi; Sandro Grelli; Arianna Gatti; Carlotta Cerva; Antonella Minutolo,; Marina Potestà; Maria Luisa Di Martino; Francesco Ortu; Paola Selva; Laura Del Pup; Irene Guarnori; Patrizia Lorenzini; Giusy Capuano; Andrea Antinori; Chiara Agrati. Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study. PLOS ONE 2019, 14, e0225415 .

AMA Style

Veronica Bordoni, Bruno Brando, Pierluca Piselli, Olindo Forini, Federico Enrico Perna, Umberto Atripaldi, Sara Carputo, Federica Garziano, Elisabetta Trento, Giovanna D'Agosto, Alessandra Latini, Manuela Colafigli, Antonio Cristaudo, Alessandra Sacchi, Massimo Andreoni, Gabriella De Carli, Nicoletta Orchi, Sandro Grelli, Arianna Gatti, Carlotta Cerva, Antonella Minutolo,, Marina Potestà, Maria Luisa Di Martino, Francesco Ortu, Paola Selva, Laura Del Pup, Irene Guarnori, Patrizia Lorenzini, Giusy Capuano, Andrea Antinori, Chiara Agrati. Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study. PLOS ONE. 2019; 14 (12):e0225415.

Chicago/Turabian Style

Veronica Bordoni; Bruno Brando; Pierluca Piselli; Olindo Forini; Federico Enrico Perna; Umberto Atripaldi; Sara Carputo; Federica Garziano; Elisabetta Trento; Giovanna D'Agosto; Alessandra Latini; Manuela Colafigli; Antonio Cristaudo; Alessandra Sacchi; Massimo Andreoni; Gabriella De Carli; Nicoletta Orchi; Sandro Grelli; Arianna Gatti; Carlotta Cerva; Antonella Minutolo,; Marina Potestà; Maria Luisa Di Martino; Francesco Ortu; Paola Selva; Laura Del Pup; Irene Guarnori; Patrizia Lorenzini; Giusy Capuano; Andrea Antinori; Chiara Agrati. 2019. "Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study." PLOS ONE 14, no. 12: e0225415.

Journal article
Published: 01 December 2019 in Journal of Refugee Studies
Reads 0
Downloads 0

In 2015, more than 1 million asylum seekers and refugees arrived in Europe. Information on how European countries addressed the prevention and control of infectious diseases among these populations during and after this period is limited. This study is based on 27 semi-structured interviews conducted with first-line staff and health officials in May–June 2016 in first-entry countries (Greece/Italy), transit countries (Croatia/Slovenia) and destination countries (Austria/Sweden). Characteristics of health-service provision for infectious diseases at each stage of reception, with a focus on tuberculosis, viral hepatitis, intestinal parasites and human immunodeficiency virus infections, were investigated. No major differences in the provision of services in accordance with migration status (asylum seekers vs refugees) were reported. At arrival, interventions were focused on addressing emerging health needs and no major barriers to accessing acute hospital care for infectious diseases were reported. There were shortcomings in interventions to tackle medium- to long-term needs with respect to infectious diseases, including screening for chronic treatable infections and adult vaccination. European evidence-based guidance highlighting the most relevant interventions for infectious diseases during the reception process is needed.

ACS Style

Pierluca Piselli; Mariya Samuilova; Kayvan Bozorgmehr; Giuseppe Ippolito; Roumyana Petrova-Benedict; Alexander Kentikelenis; Enrico Girardi. Infectious-disease Screening and Vaccination for Refugees and Asylum Seekers Entering Europe in 2015–16: A Scoping Study of Six European Union Countries. Journal of Refugee Studies 2019, 32, i92 -i104.

AMA Style

Pierluca Piselli, Mariya Samuilova, Kayvan Bozorgmehr, Giuseppe Ippolito, Roumyana Petrova-Benedict, Alexander Kentikelenis, Enrico Girardi. Infectious-disease Screening and Vaccination for Refugees and Asylum Seekers Entering Europe in 2015–16: A Scoping Study of Six European Union Countries. Journal of Refugee Studies. 2019; 32 (Special__1):i92-i104.

Chicago/Turabian Style

Pierluca Piselli; Mariya Samuilova; Kayvan Bozorgmehr; Giuseppe Ippolito; Roumyana Petrova-Benedict; Alexander Kentikelenis; Enrico Girardi. 2019. "Infectious-disease Screening and Vaccination for Refugees and Asylum Seekers Entering Europe in 2015–16: A Scoping Study of Six European Union Countries." Journal of Refugee Studies 32, no. Special__1: i92-i104.

Journal article
Published: 01 September 2019 in Health Policy
Reads 0
Downloads 0
ACS Style

Kayvan Bozorgmehr; Mariya Samuilova; Roumyana Petrova-Benedict; Enrico Girardi; Pierluca Piselli; Alexander Kentikelenis. Infectious disease health services for refugees and asylum seekers during a time of crisis: A scoping study of six European Union countries. Health Policy 2019, 123, 882 -887.

AMA Style

Kayvan Bozorgmehr, Mariya Samuilova, Roumyana Petrova-Benedict, Enrico Girardi, Pierluca Piselli, Alexander Kentikelenis. Infectious disease health services for refugees and asylum seekers during a time of crisis: A scoping study of six European Union countries. Health Policy. 2019; 123 (9):882-887.

Chicago/Turabian Style

Kayvan Bozorgmehr; Mariya Samuilova; Roumyana Petrova-Benedict; Enrico Girardi; Pierluca Piselli; Alexander Kentikelenis. 2019. "Infectious disease health services for refugees and asylum seekers during a time of crisis: A scoping study of six European Union countries." Health Policy 123, no. 9: 882-887.

Journal article
Published: 28 March 2019 in BMC Nephrology
Reads 0
Downloads 0

In southern Europe, the risk of cancer in patients with end-stage kidney disease receiving dialysis has not been well quantified. The aim of this study was to assess the overall pattern of risk for de novo malignancies (DNMs) among dialysis patients in the Friuli Venezia Giulia region, north-eastern Italy. A population-based cohort study among 3407 dialysis patients was conducted through a record linkage between local healthcare databases and the cancer registry (1998-2013). Person-years (PYs) were calculated from 30 days after the date of first dialysis to the date of DNM diagnosis, kidney transplant, death, last follow-up or December 31, 2013, whichever came first. The risk of DNM, as compared to the general population, was estimated using standardized incidence ratios (SIRs) and 95% confidence intervals (CIs). During 10,798 PYs, 357 DNMs were diagnosed in 330 dialysis patients. A higher than expected risk of 1.3-fold was found for all DNMs combined (95% CI: 1.15-1.43). The risk was particularly high in younger dialysis patients (SIR = 1.88, 95% CI: 1.42-2.45 for age 40-59 years), and it decreased with age. Moreover, significantly increased DNM risks emerged during the first 3 years since dialysis initiation, especially within the first year (SIR = 8.52, 95% CI: 6.89-10.41). Elevated excess risks were observed for kidney (SIR = 3.18; 95% CI: 2.06-4.69), skin non-melanoma (SIR = 1.81, 95% CI: 1.46-2.22), oral cavity (SIR = 2.42, 95% CI: 1.36-4.00), and Kaposi's sarcoma (SIR = 10.29, 95% CI: 1.25-37.16). The elevated risk for DNM herein documented suggest the need to implement a targeted approach to cancer prevention and control in dialysis patients.

ACS Style

Martina Taborelli; for the Italian Transplant & Cancer Cohort Study; Federica Toffolutti; Stefania Del Zotto; Elena Clagnan; Lucrezia Furian; Pierluca Piselli; Franco Citterio; Loris Zanier; Giuliano Boscutti; Diego Serraino; Sarah Shalaby. Increased cancer risk in patients undergoing dialysis: a population-based cohort study in North-Eastern Italy. BMC Nephrology 2019, 20, 107 .

AMA Style

Martina Taborelli, for the Italian Transplant & Cancer Cohort Study, Federica Toffolutti, Stefania Del Zotto, Elena Clagnan, Lucrezia Furian, Pierluca Piselli, Franco Citterio, Loris Zanier, Giuliano Boscutti, Diego Serraino, Sarah Shalaby. Increased cancer risk in patients undergoing dialysis: a population-based cohort study in North-Eastern Italy. BMC Nephrology. 2019; 20 (1):107.

Chicago/Turabian Style

Martina Taborelli; for the Italian Transplant & Cancer Cohort Study; Federica Toffolutti; Stefania Del Zotto; Elena Clagnan; Lucrezia Furian; Pierluca Piselli; Franco Citterio; Loris Zanier; Giuliano Boscutti; Diego Serraino; Sarah Shalaby. 2019. "Increased cancer risk in patients undergoing dialysis: a population-based cohort study in North-Eastern Italy." BMC Nephrology 20, no. 1: 107.

Clinical trial
Published: 01 March 2019 in AIDS
Reads 0
Downloads 0

Antiretrovirals with long half-lives, such as tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and efavirenz (EFV), are suitable for reduced frequency dosing, with potential for improved adherence and reduced toxicity and costs. The objective of this study was to investigate the noninferiority of the TDF/FTC/EFV fixed-dose combination on alternate-days versus standard regimen in virologically suppressed patients. A randomized-controlled open-label noninferiority trial enrolling HIV-1-infected patients treated for at least 6 months with TDF/FTC/EFV fixed-dose combination, virologically suppressed (Methods: Primary end-point was the proportion of patients with less than 40 HIV-RNA copies/ml at week 48. One hundred and ninety-seven patients were randomized (98 in the SOC and 99 in the ATAD arm). One hundred and seventy-nine (90.3%) were men, median age 43.2 years, 133 (67.5%) MSM. CD4+ T-cell count at baseline was 706 cells/μl in SOC and 632 cells/μl in ATAD arm. At week 48, 95 (96.9%) patients in SOC and 93 (93.9%) in ATAD had a virological response (−3.0% overall risk difference, 95% CI: −8.86%/2.86%). Median change from baseline at week 48 in CD4+ T-cell count was 29.4 cells/μl (95% CI: 2.5/56.4) in SOC (P = 0.008) and 61.0 cells/μl (95% CI: 32.1/89.9) in ATAD (P Conclusion: Despite a significant decrease of EFV exposure, TDF/FTC/EFV on ATAD was noninferior to SOC regimen through 48 weeks.

ACS Style

Rita Bellagamba; Maria Letizia Giancola; Chiara Tommasi; Pierluca Piselli; Massimo Tempestilli; Claudio Angeletti; Mauro Zaccarelli; Adriana Ammassari; Carmela Pinnetti; Anna Loredana Gallo; Andrea Antinori; Pasquale Narciso; Emanuele Nicastri. Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment. AIDS 2019, 33, 493 -502.

AMA Style

Rita Bellagamba, Maria Letizia Giancola, Chiara Tommasi, Pierluca Piselli, Massimo Tempestilli, Claudio Angeletti, Mauro Zaccarelli, Adriana Ammassari, Carmela Pinnetti, Anna Loredana Gallo, Andrea Antinori, Pasquale Narciso, Emanuele Nicastri. Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment. AIDS. 2019; 33 (3):493-502.

Chicago/Turabian Style

Rita Bellagamba; Maria Letizia Giancola; Chiara Tommasi; Pierluca Piselli; Massimo Tempestilli; Claudio Angeletti; Mauro Zaccarelli; Adriana Ammassari; Carmela Pinnetti; Anna Loredana Gallo; Andrea Antinori; Pasquale Narciso; Emanuele Nicastri. 2019. "Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment." AIDS 33, no. 3: 493-502.

Letter to the editor
Published: 06 January 2019 in International Journal of Cancer
Reads 0
Downloads 0
ACS Style

Pierluca Piselli; Martina Taborelli; Claudia Cimaglia; Diego Serraino; for the Italian Transplant & Cancer Cohort Study. Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR‐inhibitors: 1997–2016. International Journal of Cancer 2019, 145, 597 -598.

AMA Style

Pierluca Piselli, Martina Taborelli, Claudia Cimaglia, Diego Serraino, for the Italian Transplant & Cancer Cohort Study. Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR‐inhibitors: 1997–2016. International Journal of Cancer. 2019; 145 (2):597-598.

Chicago/Turabian Style

Pierluca Piselli; Martina Taborelli; Claudia Cimaglia; Diego Serraino; for the Italian Transplant & Cancer Cohort Study. 2019. "Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR‐inhibitors: 1997–2016." International Journal of Cancer 145, no. 2: 597-598.

Research article
Published: 26 October 2018 in International Journal of Cancer
Reads 0
Downloads 0

In the setting of liver transplant (LT), the survival after the diagnosis of de novo malignancies (DNMs) has been poorly investigated. In this study, we assessed the impact of DNMs on survival of LT recipients as compared to corresponding LT recipients without DNM. A nested case‐control study was conducted in a cohort of 2818 LT recipients enrolled in nine Italian centres between 1985 and 2014. Cases were 244 LT recipients who developed DNMs after LT. For each case, 2 controls matched for gender, age, and year at transplant were selected by incidence density sampling among cohort members without DNM. The survival probabilities were estimated using the Kaplan‐Meier method. Hazard ratios (HRs) of death and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models. The all‐cancer 10‐year survival was 43% in cases versus 70% in controls (HR=4.66; 95% CI: 3.17‐6.85). Survival was impaired in cases for all the most frequent cancer types, including lung (HR=37.13; 95% CI: 4.98‐276.74), non‐Hodgkin lymphoma (HR=6.57; 95% CI: 2.15‐20.01), head and neck (HR=4.65; 95% CI: 1.81‐11.95), and colon‐rectum (HR=3.61; 95% CI: 1.08‐12.07). The survival gap was observed for both early and late mortality, although the effect was more pronounced in the first year after cancer diagnosis. No significant differences in survival emerged for Kaposi's sarcoma and non‐melanoma skin cancers. The survival gap herein quantified included a broad range of malignancies following LT and prompts close monitoring during the post‐transplant follow‐up in order to ensure early cancer diagnosis and to improve survival. This article is protected by copyright. All rights reserved.

ACS Style

Martina Taborelli; Pierluca Piselli; Giuseppe Maria Ettorre; Umberto Baccarani; Patrizia Burra; Augusto Lauro; Laura Galatioto; Maria Rendina; Sarah Shalaby; Raffaella Petrara; Francesco Nudo; Luca Toti; Giovanni Fantola; Claudia Cimaglia; Alessandro Agresta; Giovanni Vennarecci; Antonio Daniele Pinna; Salvatore Gruttadauria; Andrea Risaliti; Alfredo Di Leo; Massimo Rossi; Giuseppe Tisone; Fausto Zamboni; Diego Serraino; for the Italian Transplant and Cancer Cohort Study; for the Italian Transplant & Cancer Cohort Study. Survival after the diagnosis of de novo malignancy in liver transplant recipients. International Journal of Cancer 2018, 144, 232 -239.

AMA Style

Martina Taborelli, Pierluca Piselli, Giuseppe Maria Ettorre, Umberto Baccarani, Patrizia Burra, Augusto Lauro, Laura Galatioto, Maria Rendina, Sarah Shalaby, Raffaella Petrara, Francesco Nudo, Luca Toti, Giovanni Fantola, Claudia Cimaglia, Alessandro Agresta, Giovanni Vennarecci, Antonio Daniele Pinna, Salvatore Gruttadauria, Andrea Risaliti, Alfredo Di Leo, Massimo Rossi, Giuseppe Tisone, Fausto Zamboni, Diego Serraino, for the Italian Transplant and Cancer Cohort Study, for the Italian Transplant & Cancer Cohort Study. Survival after the diagnosis of de novo malignancy in liver transplant recipients. International Journal of Cancer. 2018; 144 (2):232-239.

Chicago/Turabian Style

Martina Taborelli; Pierluca Piselli; Giuseppe Maria Ettorre; Umberto Baccarani; Patrizia Burra; Augusto Lauro; Laura Galatioto; Maria Rendina; Sarah Shalaby; Raffaella Petrara; Francesco Nudo; Luca Toti; Giovanni Fantola; Claudia Cimaglia; Alessandro Agresta; Giovanni Vennarecci; Antonio Daniele Pinna; Salvatore Gruttadauria; Andrea Risaliti; Alfredo Di Leo; Massimo Rossi; Giuseppe Tisone; Fausto Zamboni; Diego Serraino; for the Italian Transplant and Cancer Cohort Study; for the Italian Transplant & Cancer Cohort Study. 2018. "Survival after the diagnosis of de novo malignancy in liver transplant recipients." International Journal of Cancer 144, no. 2: 232-239.

Research article
Published: 04 September 2018 in Journal of the American Heart Association
Reads 0
Downloads 0

Background Glycosphingolipid accumulation in Fabry cells generates a proinflammatory response that may influence disease evolution and responsiveness to enzyme replacement therapy. This study evaluated incidence, mechanism, and impact of myocarditis in Fabry disease cardiomyopathy ( FDCM ). Methods and Results Myocarditis, defined as CD 3 + T lymphocytes >7/mm 2 associated with necrosis of glycolipid‐laden myocardiocytes, was retrospectively evaluated in endomyocardial biopsies from 78 patients with FDCM : 13 with maximal wall thickness (MWT) 20 mm (group 4). Myocarditis was investigated by polymerase chain reaction for cardiotropic viruses, by serum antiheart and antimyosin antibodies, and by cardiac magnetic resonance. Myocarditis was recognized at histology in 48 of 78 patients with FDCM (38% of group 1, 41% of group 2, 66% of group 3, and 72% of group 4). Myocarditis was characterized by positive antiheart and antimyosin antibodies and negative polymerase chain reaction for viral genomes. CD 3 + cells/mm 2 correlated with myocyte necrosis, antimyosin autoantibody titer, and MWT ( P <0.001, r =0.79; P <0.001, r =0.84; P <0.001, r =0.61, respectively). Cardiac magnetic resonance showed myocardial edema in 24 of 78 patients (31%): 0% of group 1, 23% of group 2, 37% of group 3, and 50% of group 4. Conclusions Myocarditis is detectable at histology in up to 56% of patients with FDCM . It is immune mediated and correlates with disease severity. It can be disclosed by antiheart/antimyosin autoantibodies and in the advanced phase by cardiac magnetic resonance. It may contribute to progression of FDCM and resistance to enzyme replacement therapy.

ACS Style

Andrea Frustaci; Romina Verardo; Claudia Grande; Nicola Galea; Pierluca Piselli; Iacopo Carbone; Maria Alfarano; Matteo Antonio Russo; Cristina Chimenti. Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy. Journal of the American Heart Association 2018, 7, e009052 .

AMA Style

Andrea Frustaci, Romina Verardo, Claudia Grande, Nicola Galea, Pierluca Piselli, Iacopo Carbone, Maria Alfarano, Matteo Antonio Russo, Cristina Chimenti. Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy. Journal of the American Heart Association. 2018; 7 (17):e009052.

Chicago/Turabian Style

Andrea Frustaci; Romina Verardo; Claudia Grande; Nicola Galea; Pierluca Piselli; Iacopo Carbone; Maria Alfarano; Matteo Antonio Russo; Cristina Chimenti. 2018. "Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy." Journal of the American Heart Association 7, no. 17: e009052.

Comparative study
Published: 08 May 2018 in BMC Infectious Diseases
Reads 0
Downloads 0

Chagas disease (CD) is a systemic parasitic infection caused by the protozoan Trypanosoma cruzi, whose chronic phase may lead to cardiac and intestinal disorders. Endemic in Latin America where it is transmitted mainly by vectors, large-scale migrations to other countries have turned CD into a global health problem because of its alternative transmission routes through blood transfusion, tissue transplantation, or congenital. Aim of this study was to compare the performance of two commercially available tests for serological diagnosis of CD in a group of Latin American migrants living in a non-endemic setting (Rome, Italy). The study was based on a cross-sectional analysis of seroprevalence in this group. Epidemiological risk factors associated to CD were also evaluated in this study population. The present study was conducted on 368 subjects from the Latin American community resident in Rome. Following WHO guidelines, we employed a diagnostic strategy based on two tests to detect IgG antibodies against T. cruzi in the blood (a lysate antigen-based ELISA and a chemiluminescent microparticle CMIA composed of multiple recombinant antigens), followed by a third test (an immunochromatographic assay) on discordant samples. Our diagnostic approach produced 319/368 (86.7%) concordant negative and 30/368 (8.1%) concordant positive results after the first screening. Discrepancies were obtained for 19/368 (5.2%) samples that were tested using the third assay, obtaining 2 more positive and 17 negative results. The final count of positive samples was 32/368 (8.7% of the tested population). Increasing age, birth in Bolivia, and previous residence in a mud house were independent factors associated with T. cruzi positive serology. Serological diagnosis of CD is still challenging, because of the lack of a reference standard serological assay for diagnosis. Our results reaffirm the importance of performing CD screening in non-endemic countries; employing a fully automated and highly sensitive CMIA assay first could be a cost- and resource-effective strategy for mass screening of low-risk patients. However, our results also suggest that the WHO strategy of using two different serological assays, combined with epidemiological information, remains the best approach for patients coming from endemic countries.

ACS Style

Stefania Pane; Maria Letizia Giancola; Pierluca Piselli; Angela Corpolongo; Ernestina Repetto; Rita Bellagamba; Claudia Cimaglia; Stefania Carrara; Piero Ghirga; Alessandra Oliva; Nazario Bevilacqua; Ahmad Al Rousan; Carla Nisii; Giuseppe Ippolito; Emanuele Nicastri. Serological evaluation for Chagas disease in migrants from Latin American countries resident in Rome, Italy. BMC Infectious Diseases 2018, 18, 212 .

AMA Style

Stefania Pane, Maria Letizia Giancola, Pierluca Piselli, Angela Corpolongo, Ernestina Repetto, Rita Bellagamba, Claudia Cimaglia, Stefania Carrara, Piero Ghirga, Alessandra Oliva, Nazario Bevilacqua, Ahmad Al Rousan, Carla Nisii, Giuseppe Ippolito, Emanuele Nicastri. Serological evaluation for Chagas disease in migrants from Latin American countries resident in Rome, Italy. BMC Infectious Diseases. 2018; 18 (1):212.

Chicago/Turabian Style

Stefania Pane; Maria Letizia Giancola; Pierluca Piselli; Angela Corpolongo; Ernestina Repetto; Rita Bellagamba; Claudia Cimaglia; Stefania Carrara; Piero Ghirga; Alessandra Oliva; Nazario Bevilacqua; Ahmad Al Rousan; Carla Nisii; Giuseppe Ippolito; Emanuele Nicastri. 2018. "Serological evaluation for Chagas disease in migrants from Latin American countries resident in Rome, Italy." BMC Infectious Diseases 18, no. 1: 212.

Cancer epidemiology
Published: 25 April 2018 in International Journal of Cancer
Reads 0
Downloads 0

This cohort study assessed, in Italy, the overall pattern of risk of de novo malignancies following liver transplantation (LT). The study group included 2,832 individuals who underwent LT between 1985 and 2014 in nine centers all over Italy. Person–years (PYs) at cancer risk were computed from 30 days after LT to the date of cancer diagnosis, to the date of death or to the end of follow‐up. Excess cancer risk, as compared to the general population, was estimated using standardized incidence ratios (SIRs) and 95% confidence intervals (CIs). During 18,642 PYs, 246 LT recipients developed 266 de novo malignancies, corresponding to a 1.8‐fold higher cancer risk (95% CI: 1.6–2.0). SIRs were particularly elevated for virus‐related malignancies, including Kaposi's sarcoma (SIR = 53.6, 95% CI: 30.0–88.5), non‐Hodgkin lymphomas (SIR = 7.1, 95% CI: 4.8–10.1) and cervix uteri (SIR = 5.4, 95% CI: 1.1–15.8). Among virus‐unrelated malignancies, elevated risks emerged for head and neck (SIR = 4.4, 95% CI: 3.1–6.2), esophagus (SIR = 6.7, 95% CI: 2.9–13.3) and adrenal gland (SIR = 22.9, 95% CI: 2.8–82.7). Borderline statistically significant elevated risks were found for lung cancer (SIR = 1.4, 95% CI: 1.0–2.1) and skin melanoma (SIR = 2.6, 95% CI: 1.0–5.3). A reduced risk emerged for prostate cancer (SIR = 0.1, 95% CI: 0.0–0.5). These findings underline the need of preventive interventions and early detection of malignancies, specifically tailored to LT recipients.

ACS Style

Martina Taborelli; Pierluca Piselli; Giuseppe Maria Ettorre; Augusto Lauro; Laura Galatioto; Umberto Baccarani; Maria Rendina; Sarah Shalaby; Raffaella Petrara; Francesco Nudo; Luca Toti; Daniele Sforza; Giovanni Fantola; Claudia Cimaglia; Alessandro Agresta; Giovanni Vennarecci; Antonio Daniele Pinna; Salvatore Gruttadauria; Andrea Risaliti; Alfredo Di Leo; Patrizia Burra; Massimo Rossi; Giuseppe Tisone; Fausto Zamboni; Diego Serraino; for the Italian Transplant & Cancer Cohort Study. Risk of virus and non‐virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985–2014. International Journal of Cancer 2018, 143, 1588 -1594.

AMA Style

Martina Taborelli, Pierluca Piselli, Giuseppe Maria Ettorre, Augusto Lauro, Laura Galatioto, Umberto Baccarani, Maria Rendina, Sarah Shalaby, Raffaella Petrara, Francesco Nudo, Luca Toti, Daniele Sforza, Giovanni Fantola, Claudia Cimaglia, Alessandro Agresta, Giovanni Vennarecci, Antonio Daniele Pinna, Salvatore Gruttadauria, Andrea Risaliti, Alfredo Di Leo, Patrizia Burra, Massimo Rossi, Giuseppe Tisone, Fausto Zamboni, Diego Serraino, for the Italian Transplant & Cancer Cohort Study. Risk of virus and non‐virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985–2014. International Journal of Cancer. 2018; 143 (7):1588-1594.

Chicago/Turabian Style

Martina Taborelli; Pierluca Piselli; Giuseppe Maria Ettorre; Augusto Lauro; Laura Galatioto; Umberto Baccarani; Maria Rendina; Sarah Shalaby; Raffaella Petrara; Francesco Nudo; Luca Toti; Daniele Sforza; Giovanni Fantola; Claudia Cimaglia; Alessandro Agresta; Giovanni Vennarecci; Antonio Daniele Pinna; Salvatore Gruttadauria; Andrea Risaliti; Alfredo Di Leo; Patrizia Burra; Massimo Rossi; Giuseppe Tisone; Fausto Zamboni; Diego Serraino; for the Italian Transplant & Cancer Cohort Study. 2018. "Risk of virus and non‐virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985–2014." International Journal of Cancer 143, no. 7: 1588-1594.

Journal article
Published: 11 April 2018 in Health policy (Amsterdam, Netherlands)
Reads 0
Downloads 0
ACS Style

Kayvan Bozorgmehr; Mariya Samuilova; Roumyana Petrova-Benedict; Enrico Girardi; Pierluca Piselli; Alexander Kentikelenis. Infectious disease health services for refugees and asylum seekers during a time of crisis: A scoping study of six European Union countries. Health policy (Amsterdam, Netherlands) 2018, 1 .

AMA Style

Kayvan Bozorgmehr, Mariya Samuilova, Roumyana Petrova-Benedict, Enrico Girardi, Pierluca Piselli, Alexander Kentikelenis. Infectious disease health services for refugees and asylum seekers during a time of crisis: A scoping study of six European Union countries. Health policy (Amsterdam, Netherlands). 2018; ():1.

Chicago/Turabian Style

Kayvan Bozorgmehr; Mariya Samuilova; Roumyana Petrova-Benedict; Enrico Girardi; Pierluca Piselli; Alexander Kentikelenis. 2018. "Infectious disease health services for refugees and asylum seekers during a time of crisis: A scoping study of six European Union countries." Health policy (Amsterdam, Netherlands) , no. : 1.

Journal article
Published: 01 March 2018 in Digestive and Liver Disease
Reads 0
Downloads 0
ACS Style

S. Shalaby; M. Taborelli; A. Zanetto; A. Ferrarese; C. Becchetti; S.S. Sciarrone; M. Gambato; G. Germani; M. Senzolo; F.P. Russo; G. Zanus; U. Cillo; P. Piselli; D. Serraino; P. Burra. P.09.5 ASSESSING THE RISK OF DE NOVO NEOPLASMS AFTER LIVER TRANSPLANTATION: ROLE OF HEPATOCELLULAR CARCINOMA. Digestive and Liver Disease 2018, 50, e217 -e218.

AMA Style

S. Shalaby, M. Taborelli, A. Zanetto, A. Ferrarese, C. Becchetti, S.S. Sciarrone, M. Gambato, G. Germani, M. Senzolo, F.P. Russo, G. Zanus, U. Cillo, P. Piselli, D. Serraino, P. Burra. P.09.5 ASSESSING THE RISK OF DE NOVO NEOPLASMS AFTER LIVER TRANSPLANTATION: ROLE OF HEPATOCELLULAR CARCINOMA. Digestive and Liver Disease. 2018; 50 (2):e217-e218.

Chicago/Turabian Style

S. Shalaby; M. Taborelli; A. Zanetto; A. Ferrarese; C. Becchetti; S.S. Sciarrone; M. Gambato; G. Germani; M. Senzolo; F.P. Russo; G. Zanus; U. Cillo; P. Piselli; D. Serraino; P. Burra. 2018. "P.09.5 ASSESSING THE RISK OF DE NOVO NEOPLASMS AFTER LIVER TRANSPLANTATION: ROLE OF HEPATOCELLULAR CARCINOMA." Digestive and Liver Disease 50, no. 2: e217-e218.

Journal article
Published: 01 February 2018 in Digestive and Liver Disease
Reads 0
Downloads 0
ACS Style

S. Shalaby; M. Taborelli; A. Zanetto; A. Ferrarese; C. Becchetti; S.S. Sciarrone; M. Gambato; G. Germani; M. Senzolo; F.P. Russo; G. Zanus; U. Cillo; P. Piselli; D. Serraino; P. Burra. Assessing the risk of de novo neoplasms after liver transplantation: Role of pre-transplant hepatocellular carcinoma. Digestive and Liver Disease 2018, 50, 35 .

AMA Style

S. Shalaby, M. Taborelli, A. Zanetto, A. Ferrarese, C. Becchetti, S.S. Sciarrone, M. Gambato, G. Germani, M. Senzolo, F.P. Russo, G. Zanus, U. Cillo, P. Piselli, D. Serraino, P. Burra. Assessing the risk of de novo neoplasms after liver transplantation: Role of pre-transplant hepatocellular carcinoma. Digestive and Liver Disease. 2018; 50 (1):35.

Chicago/Turabian Style

S. Shalaby; M. Taborelli; A. Zanetto; A. Ferrarese; C. Becchetti; S.S. Sciarrone; M. Gambato; G. Germani; M. Senzolo; F.P. Russo; G. Zanus; U. Cillo; P. Piselli; D. Serraino; P. Burra. 2018. "Assessing the risk of de novo neoplasms after liver transplantation: Role of pre-transplant hepatocellular carcinoma." Digestive and Liver Disease 50, no. 1: 35.